{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T05:38:43Z","timestamp":1792647523798,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.jpba.2018.09.042","type":"journal-article","created":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T20:25:06Z","timestamp":1537475106000},"page":"286-290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Development and validation of a method using ultra performance liquid chromatography coupled to tandem mass spectrometry for determination of zoledronic acid concentration in human bone"],"prefix":"10.1016","volume":"162","author":[{"given":"Alfredo Fabrizio","family":"Lo Faro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Giorgetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3082-4532","authenticated-orcid":false,"given":"Francesco Paolo","family":"Busard\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0218-8292","authenticated-orcid":false,"given":"Giovanni","family":"Lodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4010-3736","authenticated-orcid":false,"given":"Alberto","family":"Pispero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5063-1236","authenticated-orcid":false,"given":"Marcello","family":"Iriti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7287-2188","authenticated-orcid":false,"given":"Elena Maria","family":"Varoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 3","key":"10.1016\/j.jpba.2018.09.042_bib0005","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1093\/ajhp\/58.suppl_3.S16","article-title":"Advances in the biology and treatment of myeloma bone disease","volume":"58","author":"Berenson","year":"2001","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"2 Suppl 3","key":"10.1016\/j.jpba.2018.09.042_bib0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0037-1963(01)90090-3","article-title":"New advances in the biology and treatment of myeloma bone disease","volume":"38","author":"Berenson","year":"2001","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.jpba.2018.09.042_bib0015","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2362.1970.tb00591.x","article-title":"The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo","volume":"1","author":"Fleisch","year":"1970","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.jpba.2018.09.042_bib0020","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","article-title":"Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite","volume":"38","author":"Nancollas","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.jpba.2018.09.042_bib0025","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/BF02196199","article-title":"The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats","volume":"6","author":"Russell","year":"1970","journal-title":"Calcif. Tissue Res."},{"key":"10.1016\/j.jpba.2018.09.042_bib0030","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.jpba.2018.09.042_bib0035","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2018.09.042_bib0040","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1834-7819.2010.01283.x","article-title":"A review of the clinical implications of bisphosphonates in dentistry","volume":"56","author":"Borromeo","year":"2011","journal-title":"Aust. Dent. J."},{"key":"10.1016\/j.jpba.2018.09.042_bib0045","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1749-6632.2010.05771.x","article-title":"Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients","volume":"1218","author":"Hoff","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jpba.2018.09.042_bib0050","first-page":"39","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphanates","volume":"31","author":"Pavkovic","year":"2010","journal-title":"Prilozi"},{"key":"10.1016\/j.jpba.2018.09.042_bib0055","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jpba.2018.09.042_bib0060","first-page":"38","article-title":"Bisphosphonate-associated osteonecrosis: a clinician\u2019s reference to patient management","volume":"20","author":"Grewal","year":"2008","journal-title":"Todays FDA"},{"key":"10.1016\/j.jpba.2018.09.042_bib0065","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/8756-3282(96)00182-2","article-title":"Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones","volume":"19","author":"Masarachia","year":"1996","journal-title":"Bone"},{"key":"10.1016\/j.jpba.2018.09.042_bib0070","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1517\/17425255.4.11.1371","article-title":"Skeletal accumulation of bisphosphonates: implications for osteoporosis treatment","volume":"4","author":"Allen","year":"2008","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.jpba.2018.09.042_bib0075","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jchromb.2013.07.019","article-title":"Quantitation of zoledronic acid in murine bone by liquid chromatography coupled with tandem mass spectrometry","volume":"935","author":"Raccor","year":"2013","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2018.09.042_bib0080","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1002\/rcm.2755","article-title":"A general approach for the quantitative analysis of bisphosphonates in human serum and urine by high-performance liquid chromatography\/tandem mass spectrometry","volume":"20","author":"Zhu","year":"2006","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.jpba.2018.09.042_bib0085","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.jchromb.2011.05.037","article-title":"Determination of zoledronic acid in human urine and blood plasma using liquid chromatography\/electrospray mass spectrometry","volume":"879","author":"Veldboer","year":"2011","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2018.09.042_bib0090","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0731-7085(02)00218-2","article-title":"Development and validation of a highly sensitive RIA for zoledronic acid, a new potent heterocyclic bisphosphonate, in human serum, plasma and urine","volume":"30","author":"Legay","year":"2002","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2018.09.042_bib0095","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.apradiso.2011.12.019","article-title":"Development of superior bone scintigraphic agent from a series of (99m)Tc-labeled zoledronic acid derivatives","volume":"70","author":"Lin","year":"2012","journal-title":"Appl. Radiat. Isot."},{"key":"10.1016\/j.jpba.2018.09.042_bib0100","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1124\/dmd.108.021071","article-title":"Biodistribution and plasma protein binding of zoledronic acid","volume":"36","author":"Weiss","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jpba.2018.09.042_bib0105","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1601-0825.2010.01772.x","article-title":"Anatomic site variability in rat skeletal uptake and desorption of fluorescently labeled bisphosphonate","volume":"17","author":"Wen","year":"2011","journal-title":"Oral Dis."},{"key":"10.1016\/j.jpba.2018.09.042_bib0110","first-page":"5442","article-title":"Update of standard practices for new method validation in forensic toxicology","volume":"23","author":"Wille","year":"2017","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jpba.2018.09.042_bib0115","first-page":"5455","article-title":"Method development in forensic toxicology","volume":"23","author":"Peters","year":"2017","journal-title":"Curr. Pharm. Des."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708518318211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708518318211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T09:52:41Z","timestamp":1571910761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708518318211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":23,"alternative-id":["S0731708518318211"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2018.09.042","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of a method using ultra performance liquid chromatography coupled to tandem mass spectrometry for determination of zoledronic acid concentration in human bone","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2018.09.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}